Arvinas (ARVN)
(Delayed Data from NSDQ)
$24.83 USD
+0.93 (3.89%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $24.83 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Arvinas, Inc. [ARVN]
Reports for Purchase
Showing records 121 - 140 ( 210 total )
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Hits New High with More Upside to Go. Increasing PT to $120.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
PROTAC Technology Has Our Ardent Support; Reiterate Buy and Raise PT to $100
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARV-471 Consistent with Best-in-Class Potential; ARV-110 Improves; PT to $93
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Key Clinical Milestones Expected in December 2020 Sets High Expectations for 2021; Reit Buy and $60 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Update - Bargain Valuation With Year-end Catalysts. Reiterate Buy.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Program Updates Ahead for ARV-471 and ARV-110
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts Following the 3rd Annual Targeted Protein Degradation Summit
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Key Takeaways from Our Talk Series
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Expansion Showcases The Broad Potential of Arvinas'' PROTACs
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
An Update on ARV-471 Program Ahead of Data Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Reiterating Buy Ahead of 4Q20 Data Readout - $65 Price Target
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z